In the April–June 2014 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory Bell and other industry experts discuss pharma and biotech patent litigation.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...